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Abstract
Purpose: To study the safety and hypotensive effect of trabeculotomy augmented
by postoperative topical medical treatment in patients with open-angle glaucoma
and to compare with trabeculectomy augmented by mitomycin C.
Methods: Inanon-randomized consecutive case series, we studied 82 patients with
open-angle glaucoma who underwent trabeculotomyaugmented by postoperative
medical therapy or trabeculectomy augmented with Mitomycin C. Forty-two pa‐
tients underwent trabeculotomyfollowed by latanoprost 0.004%, timololmaleate XE
0.5% and brinzolamide 1% and 40 patients underwent trabeculectomy augmented
with Mitomycin C. Patients were followed-up for 12 months and a success rate
based on intraocular pressure was compared.
Results: Mean baseline intraocular pressure was27.9 ± 5.4 mmHg in the trabeculoto‐
my group and 28.3 ± 4.2 mmHg in the trabeculectomy group (P = 0.7). Mean postop‐
erative intraocular pressure was 15.1 ± 2.1 mmHg at 3 months, 14.7 ± 2.1 mmHg at 6
months, and 14.9 ± 2.0 mmHg at 12 months in the trabeculotomy group and 12.2 ±
1.9 mmHg at 3 months, 12.8 ± 3.0 mmHg at 6 months, and 13.9 ± 4.2mmHg at 12
months in the trabeculectomy group.Mean intraocular pressure in the trabeculoto‐
mygroup was significantly higher than that in the trabeculectomy group at 3 and 6
months (P < 0.0001 at 3 months; P = 0.0005 at 6 months) and there was no significant
difference between the two groups at 12 months (P = 0.1). At 12 months, 42 patients
(100%) in the trrabeculotomy group and 37 patients (92.5 %) in the traberculectomy
group achieved an intraocular pressure of less than or equal to 20 mmHg and a
minimum of 30 percent reduction (P = 0.1). In the trabeculectomy group, 15 patients
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(37.5 %) received laser suture lysis,6 patients (15.0 %) underwent needling proce‐
dure, and 3 patients (7.5 %) underwent additional surgery, although no patient in
the trabeculotomy group received postoperative intervention except for topical
medical treatment. In the trabeculotomy group, patients with higher preoperative
intraocular pressure showed a significantly higher intraocular pressure at 12
months postoperatively (P < 0.0001), although there was no significant correlation
between them in the trabeculectomy group.
Conclusions: There was no significant difference in hypotensive efficacy between
patients undergoing trabeculotomyaugmented by postoperative topical medica‐
tions and those undergoing trabeculectomyaugmented by Mitomycin Cat 12
months. In those receiving trabeculotomy, patients with higher preoperative intra‐
ocular pressure showed a significantly higher intraocular pressure at 12 months
even though less than 20 mmHg.
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1. Introduction
Trabeculectomy has been a standard procedure for medically uncontrollable glaucoma [1].
Serious postoperative complications are not infrequently associated with trabeculectomy [2-5].
These include flat anterior chamber, hypotony and choroidal detachment caused by overfil‐
tration, late-onset bleb-related complications, including endophthalmitis, and cataract
progression. Shigeeda et al. demonstrated that 44.5% of patients who had undergone trabe‐
culectomy augmented with mitomycin C showed a success defined as an intraocular pressure
of less than 16 mm Hg after 8 years [6]. However, Tanihara et al. demonstrated that medical
treatment following trabeculotomy provided an additional intraocular pressure reduction and
that this surgery produced long-term stability of intraocular pressure control [7]. Trabeculot‐
omy infrequently causes serious complications and seldom requires additional postoperative
interventions [8, 9]. The aim of this study is to study the safety and hypotensive effect of
trabeculotomy augmented by postoperative medical treatment in patients with open-angle
glaucoma and to compare with trabeculectomy augmented by mitomycin C.
2. Patients and methods
In a non-randomized consecutive case series, we studied 82 patients with open-angle glaucoma
who underwent trabeculotomy augmented by postoperative medical therapy or trabeculec‐
tomy augmented with mitomycin C. A diagnosis of glaucoma was on the gonioscopic finding
along with appearance of the optic nerve head cupping and visual alteration according to the
guideline of Japan Glaucoma Society [10]. Excluded were patients with angle-closure glauco‐
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ma or posttraumatic, uveitic, neovascular, or dysgenetic glaucoma, as well as patients
undergoing previous ocular surgery. Before March, 2010, all patients underwent trabeculec‐
tomy augmented with mitomycin C, and after April, 2010, all patients underwent trabeculot‐
omy followed by latanoprost 0.004% (Xalatan™, Pfizer, New York, NY, USA), timolol maleate
XE 0.5% (Timoptol XE 0.5%™, Santen, Osaka, Japan), and brinzolamide 1% (Azopt™, Alcon,
Fort Worth, TX, USA). Patients were followed up for 12 months and the success rate based on
intraocular pressure was compared. The study protocol and consent forms were approved by
the Human Subjects Committee. When both eyes were eligible, the right eye became the study
eye.
3. Surgical procedure
Trabeculectomy: All surgeries were performed by a single surgeon. A modified Cairns-type
technique was performed [1]. After making a fornix-based conjunctival flap and dissecting a
limbus-based 4 x 4-mm scleral flap, mitomycin C 0.04%-soaked sponges were placed under‐
neath the conjunctival flap for 3 minutes. Afterward, 250 ml of balanced salt solution (Balanced
Salt Solution Plus™; Alcon, Fort Worth, TX, USA) was used to wash the surgical area.
Paracentesis was carried out followed by a peripheral iridectomy. A scleral flap was sutured
with 10/0 nylon, and a conjunctival flap was also sutured with 10/0 nylon with wing stretch
technique.
If the bleb was flat or the intraocular pressure was not low enough, laser suture lysis was
carried out. If the bleb became flat or localized, needling with angled V-lance was carried out.
Trabeculotomy: After making a fornix-based conjunctival flap, a 4 x 4-mm 4/5 thickness
limbus-based scleral flap was created. The outer wall of the Schlemm’s canal was incised and
removed. The Nagata’s semicircular trabeculotome probe was inserted into the Schlemm’s
canal, and an ocular viscoelastic device (Healon 1%™, Abbott Medical Optics, Santana, CA,
USA) was filled in the anterior chamber to reduce postoperative hyphema. The trabeculotome
was in-rotated to disrupt the inner wall of the canal, and the viscoelastic material was manually
replaced with balanced salt solution. The scleral flap was then sutured watertight with seven
10/0 nylon sutures.
4. Evaluation of outcomes
All patients underwent a detailed ophthalmic examination, including Humphrey visual field
analysis and gonioscopy. Patient progress was reviewed at 1 and 3 days; 1 and 2 weeks; and
1, 2, 3, 4, 5, 6, 9, and 12 months after surgery, and intraocular pressure was studied. Intraocular
pressure was measured with a Goldman applanation tonometer. Three measurements were
recorded in each eye, the mean of which was used in the calculations, with an interval of 2
weeks before surgery at the same time (±1:00). Postoperatively, intraocular pressure was
measured at the same time (±1:00) as at baseline. The optic nerve was examined with a
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Goldman three-mirror lens and measurements were taken of the size of the disk, the vertical
and horizontal cup/disk ratios, the presence of rim notching or splinter hemorrhage, and the
presence of peripapillary atrophy. Visual field testing with a Humphrey visual field analyzer
(Humphrey-Zeiss, Dublin, CA, USA), Program 30-2 SITA STNADARD™ testing was carried
out before surgery and at 6 and 12 months after surgery. Best-corrected visual acuity was
measured at the 1-, 2-, 3-, 4-, 5-, 6-, 9-, and 12-month visits, and the logarithm of the minimum
angle of resolution (logMAR) was calculated and used for all statistical analyses.
The presence of complications was determined intraoperatively and at every postoperative
visit. Hypotony was defined as an intraocular pressure of less than 4 mm Hg after surgery. A
shallow anterior chamber was defined as reported by Teehasaenee and Ritch [11]. An intra‐
ocular pressure spike was defined as an intraocular pressure on the first postoperative day of
greater than or equal to 3 mm Hg higher than the preoperative level.
The surgery was considered as a success with an intraocular pressure between 6 and 20 mm
Hg and an intraocular pressure reduction of greater than or equal to 30% without additional
surgery, compared to the preoperative level with medical therapy. A failure was defined when
an eye required further glaucoma surgery or lost visual function.
In case of postoperative intraocular pressure measurements of greater than 21 mm Hg in the
trabculectomy group, despite all procedures including laser suture lysis, 5-fluorouracil
injection, and needling, intraocular pressure-lowering medication was added. In case of
complications requiring surgery or still inadequate intraocular pressure control in both groups,
additional procedures could be performed as required.
Study End. All patients were meant to reach a 12-month follow-up, but the following were
considered as endpoints: (1) the need for any further surgical procedure (except laser suture
lysis, 5-fluorouracil injection, and needling); (2) an intraocular pressure of greater than 21 mm
Hg on two consecutive visits; and (3) patient failure to attend scheduled visits, allowing for a
margin of tolerance. If the study was ended before month 12, the last values obtained in the
trial were considered as the final data.
5. Statistical analysis
The sample size was chosen to assure a power of at  least 90% in detecting at least a 2-
mm Hg difference between groups with a standard deviation of  2 mm Hg with a two-
sided α error of 5%.
Evaluation of continuous variables was achieved using the Student’s t-test. To evaluate the
difference in intraocular pressures between follow-up intervals, the paired t-test was used. All
t-tests were two-tailed. Categoric variables were evaluated with the chi-square test, the Fisher
exact test, or the Spearman rank correlation as appropriate. A level of P < 0.05 was accepted as
statistically significant. Each potential confounding variable was screened for association with
the outcome. Only those confounding variables that were statistically associated were eligible
to be incorporated into the potential final multivariate model.
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For the pairing of groups, age, sex, best-corrected visual acuity, and intraocular pressure at
baseline were used for matching. We studied a correlation between the paired observations.
If observations were correlated, the F-test was used to study two population variances.
Because a representation of mean intraocular pressure over time could be misleading because
of exclusion of cases after failure, the mean intraocular pressure was recalculated by carrying
forward the last intraocular pressure reading before repeat surgery. The proportion of surgical
failures and adverse events in each treatment group was compared. Success was evaluated on
the basis of Kaplan-Meier cumulative probability (log rank test).
6. Results
Table 1 shows the demographics of the patients. Forty-two patients underwent trabeculotomy
followed by latanoprost 0.004%, timolol XE 0.5%, and brinzolamide 1%, and 40 patients
underwent trabeculectomy augmented with mitomycin C.
Trabeculotomy augmented by
postoperative medication
group
Trabeculectomy group P
Number of patients 42 40
Age (years) 63.3 ± 9.7
(38 - 78)
67.2 ± 8.2
(41 - 81)
0.1
Gender 24 men, 18 women 18 men, 22 women 0.3
Best-corrected visual acuity 0.681
(0.02 – 1.0)
0.752
(0.1 – 1.0)
-
LogMAR best-corrected visual
acuity
0.166±0.338 0.124±0.195 0.3
HFA30-2 MD (dB) -15.55 ± 6.32
(-26.33 - -4.91)
-16.20 ± 5.10
(-27.48 - -4.88)
0.7
Intraocular pressure (mmHg) 27.9 ± 5.4 (23 – 46) 28.3 ± 4.2 (23 – 42) 0.7
Number of anti- glaucomatous
drugs
3.1 ± 0.7 (2 to 4) 3.2 ± 0.7 (2 to 4) 0.9
LogMAR : Log of the minimum angle of resolution
HFA 30-2 MD: Humphrey visual field analyzer Program 30-2 Mean deviation
Parenthesis indicates a range.
Table 1. Demographics of Patients
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Mean baseline intraocular pressure was 27.9 ± 5.4 mm Hg in the trabeculotomy group and 28.3
± 4.2 mm Hg in the trabeculectomy group (P = 0.7). Mean postoperative intraocular pressure
was 15.1 ± 2.1 mm Hg at 3 months, 14.7 ± 2.1 mm Hg at 6 months, and 14.9 ± 2.0 mm Hg at 12
months in the trabeculotomy group, and it was 12.2 ± 1.9 mm Hg at 3 months, 12.8 ± 3.0 mm
Hg at 6 months, and 13.9 ± 4.2 mm Hg at 12 months in the trabeculectomy group (Figure 1,
Table 2). Mean intraocular pressure in the trabeculotomy group was significantly higher than
that in the trabeculectomy group at 3 and 6 months (P < 0.0001 at 3 months; P = 0.0005 at 6
months), and there was no significant difference between the groups at 12 months (P = 0.1). At
12 months, 42 patients (100 %) in the trabeculotomy group and 37 patients (92.5 %) in the
trabeculectomy group achieved an intraocular pressure of less than or equal to 20 mm Hg and
a minimum of 30 percent reduction (P = 0.1) (Figure 2, Table 3).
Figure 1. Trabeculotomy
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Figure 2. Trabeculotomy
Trabeculotomy augmented by
postoperative medication
group
Trabeculectomy group P
Intraocular pressure (mmHg)
Baseline 27.9 ± 5.4 (23 – 46) 28.3 ± 4.2 (23 – 42) 0.7
1 month 15.1 ±2.1 (11 – 20) 10.3 ± 2.0 (8 – 17) <0.0001
3 months 15.1 ±2.1 (11 – 20) 12.2 ± 1.9 (8 – 23) <0.0001
6 months 14.7 ± 2.1 (12 – 20) 12.8 ± 3.0 (8 - 23) 0.0005
9 months 14.9 ± 1.9 (12 – 18) 13.4 ± 3.7 (8 - 24) 0.0113
12 months 14.9 ± 2.0 (12 – 20) 13.9 ± 4.2 (8 – 25) 0.1
Intraocular pressure (mmHg)
1 month -12.7 ± 4.7 (-28 - -8) -18.0 ± 4.4 (-31 - -11) <0.0001
3 months -12.9 ± 4.1 (-26 - -8) -16.2 ± 4.5 (-31 - -10) 0.0008
6 months -13.2 ± 4.3 (-28 - -9) -15.5 ± 4.9 (-30 - -5) 0.0335
9 months -13.0 ± 4.5 (-28 - -7) -15.0 ±5.0 (-30 - -5) 0.1
12 months -13.1 ± 4.3 (-28 - -8) -14.5 ± 5.3 (-30 - -3) 0.2
Intraocular pressure (%)
1 month -44.3 ± 8.4
(-65.8 - -28.6)
-64.4 ± 8.0
(-80.6 - -44.0)
<0.0001
3 months -44.9 ± 8.7
(-65.8 - -28.6)
-57.2 ± 8.5
(-73.8 - -41.7)
<0.0001
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6 months -46.6 ± 6.7
(-63.2 - -36.0)
-54.4 ± 11.3
(-71.4 - -17.9)
0.0003
9 months -45.8 ± 7.4
(-60.9 - -29.2)
-53.0 ± 12.7
(-71.4 - -17.9)
0.0023
12 months -46.1 ± 6.9
(-60.9 - -33.3)
-51.0 ± 14.4
(-71.4 - -10.7)
0.1
Parenthesis indicates a range.
Table 2. Intraocular pressure change
Trabeculotomy augmented by
postoperative medication
group
Trabeculectomy group P
Baseline
Intraocular pressure 27.9 ± 5.4 (23 – 46) 28.3 ± 4.2 (23 – 42) 0.7
Number of anti-glaucomatous
medication
3.1 ± 0.7 (2 to 4) 3.2 ± 0.7 (2 to 4) 0.9
At 12 months
Intraocular pressure 14.9 ± 2.0 (12 – 20) 13.9 ± 4.2 (8 – 25) 0.1
Success 42 (100.0 %) 37 (92.5 %) 0.1
Failure 0 (0 %) 3 (7.5 %)
<16 mmHg 37 (84.0 %) 33 (82.5 %) 0.5
<12 mmHg 8 (19.0 %) 23 (57.5 %) 0.0211
Number of anti-glaucomatous
medications
3.0 ± 0.0 (3) 0.5 ± 0.9 (0 - 3) <0.0001
Parenthesis indicates a range.
Table 3. Surgical outcome at 12 months
7. Relationship between intraocular pressure before surgery and at 12
months after surgery
Figure 3 shows the relationship between intraocular pressure before surgery and 12 months
after surgery. In both groups, there was a significant increase in the intraocular pressure
reduction in relation to an increase in preoperative intraocular pressure (mm Hg: P < 0.0001
in both groups; %: P < 0.0001 in the trabeculotomy group, P = 0.1 in the trabeculectomy group).
In the trabeculotomy group, patients with higher preoperative intraocular pressure showed a
significantly higher intraocular pressure at 12 months postoperatively (P < 0.0001), although
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there was no significant correlation between them in the trabeculectomy group (P = 0.2) (Figure
3). At 12 months, 8 eyes (19.0 %) in the trabeculotomy group and 23 eyes (57.5 %) in the
trabeculectomy group achieved an intraocular pressure of less than or equal to 12 mm Hg, and
there was a significant difference between the two groups (P = 0.0211) (Table 3).
Figure 3. Trabeculotomy
8. Postoperative intraocular pressure-lowering procedures
In the trabeculectomy group, 15 patients (37.5 %) received laser suture lysis, 6 patients (15.0
%) underwent needling procedure, and 3 patients (7.5 %) underwent additional surgery,
although no patients in the trabeculotomy group received any postoperative intervention
except for topical medical treatment (Table 4).
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Trabeculotomy augmented by
postoperative medication group
Trabeculectomy group P
Number of patients 42 40
Topical medication 42 (100.0%) 8 (20.0%) 0.0023
Laser suture lysis 0 (0%) 15 (37.5%) < 0.0001
Needling 0 (0%) 6 (15.0%) 0.0091
5-fluorouracil injection 0 (0%) 0 (0%) -
Additional surgery 0 (0%) 3 (7.5%) 0.1
Table 4. Postoperative intraocular pressure-lowering procedure
9. Incidence of complications and adverse events
Complications are listed in Table 5. In the trabeculectomy group, 5 eyes (12.5 %) exhibited
hypotony and flat/shallow anterior chamber. In the trabeculotomy group, hyphema was
observed in 14 eyes (33.3 %) and intraocular pressure spike in 3 eyes (7.1 %). All the bleeding
disappeared within one week. No progression of cataract was found in the two groups.
Trabeculotomy augmented
by postoperative medication
group
Trabeculectomy group P
Hypotension 0 (0%) 5 (12.5%) 0.0181
Shallow/flat anterior chamber 0 (0%) 5 (12.5%) 0.0181
Choroidal detachment 0 (0%) 1 (2.5%) 0.3
Intraocular pressure spike 3 (7.1%) 0 (0%) 0.1
Hyphaema 14 (33.3%) 2 (5.0%) 0.0012
Flat bleb - 5 (12.5%) -
Anterior iris synechia 0 (0%) 0 (0%) -
Posterior iris synechia 0 (0%) 0 (0%) --
Progression of cataract 0 (0%) 0 (0%) -
Blebitis/endophthalmitis 0 (0%) 0 (0%) -
Table 5. Incidence of complications
10. Discussion
There was no significant difference in hypotensive efficacy between patients undergoing
trabeculotomy augmented by postoperative topical medication and those undergoing
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trabeculectomy augmented by mitomycin C at 12 months postoperatively. In the current study,
42 eyes (100 %) in the trabeculotomy group and 37 eyes (92.5%) in the trabeculectomy group
were considered to be a success defined as an intraocular pressure of less than or equal to 20
mm Hg and a minimum of 30 percent reduction. There was no significant difference in the
success rate or intraocular pressure between the trabeculotomy group and the trabeculectomy
group at 12 months although the intraocular pressure was higher in the trabeculotomy group
at every visit after surgery.
Each surgery had its own advantage. In the trabeculotomy group, all patients showed an
intraocular pressure of less than or equal to 20 mm Hg at 12 months. However, patients with
higher preoperative pressure showed a relatively higher intraocular pressure at 12 months
even though it was less than 20 mm Hg. There was a significant increase in the intraocular
pressure at 12 months in relation to the increase in preoperative intraocular pressure. Postop‐
erative intraocular pressure was calculated from the preoperative intraocular pressure by
using a correlation equation as follows:
[Intraocular pressure at 12 months] = 0.26 x [preoperative intraocular pressure] + 7.71 (r2=0.440,
P < 0.0001).
Patients receiving trabeculotomy experienced less postoperative surgical interventions than
those receiving trabeculectomy. In addition, 3 patients in the trabeculectomy group underwent
additional surgery although no patient in the trabeculotomy group did.
In contrast to the trabeculotomy group, there was no significant correlation between preop‐
erative intraocular pressure and postoperative intraocular pressure in patients undergoing
trabeculectomy augmented by mitomycin C. This procedure can be employed in all patients
to achieve lower postoperative pressure regardless of how high the preoperative intraocular
pressure might be. At 12 months, there was a significantly larger percent of eyes of less than
or equal to 12 mm Hg in patients undergoing trabeculectomy compared with trabeculotomy
despite of postoperative medications. Several investigators have demonstrated that it was
pivotal to set a target pressure and achieve it based on patients’ visual function [12-15]. Patients
with greater visual function deterioration need lower target pressures to maintain residual
visual function. According to the target pressure, indication for each of these methodologies
should be carefully considered prior to any surgical interventions.
This study has important limitations. The sample size of this study was small, therefore not
powered to detect small differences. The small sample size also precluded assessment of safety.
Furthermore, a masked study design could have reduced observer bias. The postoperative
follow-up period also was short, and therefore we could not assess long-term efficacy and
safety.
Although the sample size in each group was small, the current study demonstrated that (1)
there was no significant difference in hypotensive efficacy between patients undergoing
trabeculotomy augmented by postoperative topical medications and those undergoing
trabeculectomy augmented by mitomycin C at 12 months postoperatively and (2) in those
receiving trabeculotomy, patients with higher preoperative pressure showed a significantly
higher intraocular pressure at 12 months even though less than 20 mm Hg. Future study of a
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large population is needed to verify these observations. However, this information may be
clinically valuable when treating patients with open-angle glaucoma.
Author details
Hiroshi Kobayashi*
Address all correspondence to: kobi@earth.ocn.ne.jp
Department of Ophthalmology, Kanmon Medical Center, Shimonoseki, Japan
No Financial support has been received by any authors and none of the authors has any pro‐
prietary interest in the subject matter presented.
References
[1] Cairns DE. Trabeculectomy – a preliminary report of a new method. Am J Ophthal‐
mol 1968;66:673-679.
[2] Lehmann OJ, Bunce C, Matheson MM, Maurino V, et al. Risk factors for develop‐
ment of post-trabeculectomy endophthalmitis. Br J Ophthalmol 2000;84:1349-1353.
[3] Poulsen EJ, Allingham RR. Characteristics and risk factors of infections after glauco‐
ma filtering surgery. J Glaucoma 2000;9:438-443.
[4] DeBry PW, Perkins TW, Heatley G, Kaufman P, et al. Incidence of late-onset bleb-re‐
lated complications following trabeculectomy with mitomycin. Arch Ophthalmol
2002;120:297-300.
[5] Rothman RF, Liebmann, Ritch R. Low-dose 5-fluorouracil trabeculectomy as initial
surgery in uncomplicated glaucoma: long-term follow-up. Ophthalmology
2000;107:1184-1190.
[6] Shigeeda T, Tomidokoro A, Chen YN, Shirato S et al. Long-term follow-up of initial
trabeculectomy with mitomycin C for primary open-angle glaucoma in Japanese pa‐
tients. J Glaucoma 2006;15:195-199.
[7] Tanihara H, Negi A, Akimoto M, Terauchi H et al. Surgical effects of trabeculotomy
ab externo on adult eyes with primary open angle glaucoma and pseudoexfoliation
syndrome. Arch Ophthalmol 1993;111:1653-1661.
[8] Grehn F. The value of trabeculotomy in glaucoma surgery. Curr Opin Ophthalmol
1995;6:52-60.
Advances in Eye Surgery102
[9] Chihara E, Nishida A, Kodo M, Yoshimura N et al. Trabeculotomy ab externo: an al‐
ternative treatment in adult patients with primary open-angle glaucoma. Ophthalmic
Surg 1993; 24:735-739.
[10] The Japan Glaucoma Society guidelines of glaucoma (3rd edition). Nippon Ganka
Gakkai Zasshi 2012;116:387-425.
[11] Teehasaenee C, Ritch R. The use of PhEA 34c in trabeculectomy. Ophthalmology
1986;93:487-490.
[12] Palmberg P. How clinical trial results are changing our thinking about target pres‐
sures. Curr Opin Ophthalmol 2002;13:85-88.
[13] Chen PP. Correlation of visual progression between eyes in patients with open-angle
glaucoma. Ophthalmology 2002;109:2093-2099.
[14] Palmberg P. Evidence-based target pressures: how to choose and achieve them. Int
Ophthalmol Clin 2004;20:393-400.
[15] Aoyama A, Ishida K, Sawada A, Yamamoto T. Target intraocular pressure for stabili‐
ty of visual field loss progression in normal-tension glaucoma. Jpn J Ophthalomol
2010;54:117-123.
Trabeculotomy Augmented by Postoperative Topical Medications vs. Trabeculectomy Augmented by Mitomycin C
http://dx.doi.org/10.5772/60089
103

